Skip to content
  • Tuesday, 27 October 2026
  • 9:34 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Eli Lilly’s Retatrutide Achieves Unprecedented Weight Loss in TRIUMPH-1 Trial, Signaling New Era in Obesity Pharmacotherapy
Pharmaceutical R&D

Eli Lilly’s Retatrutide Achieves Unprecedented Weight Loss in TRIUMPH-1 Trial, Signaling New Era in Obesity Pharmacotherapy

Teuku Ryan Jun 18, 2026 0

NEW ORLEANS, LOUISIANA – At the 86th Scientific Sessions of the American Diabetes Association (ADA) held in New Orleans, Louisiana,…

Read More
Pharmaceutical R&D

Revolution Medicines’ Daraxonrasib Achieves Landmark Survival Extension in Pancreatic Cancer, Heralding New Era of Targeted Therapy

Teuku Ryan Jun 2, 2026 0

The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer. The 2026…

Read More
Advanced Materials Science

Quantum Metasurface Integration Breakthrough Achieves Twenty-Fold Efficiency Gain in Terahertz Radiation Detection

Nila Kartika Wati Jun 1, 2026 0

The detection of electromagnetic radiation across various spectra serves as the backbone of modern technological infrastructure, facilitating everything from fiber-optic…

Read More
Advanced Materials Science

International Research Team Achieves Breakthrough in Long Distance Quantum Key Distribution Using Semiconductor Quantum Dots and Time Bin Encoding

Nila Kartika Wati May 25, 2026 0

The landscape of global cybersecurity is on the precipice of a paradigm shift as researchers move closer to realizing a…

Read More
Laboratory Automation & Robotics

Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial

Lana Keisha May 4, 2026 0

Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…

Read More
Laboratory Automation & Robotics

Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial

Lana Keisha Apr 27, 2026 0

Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…

Read More
Laboratory Automation & Robotics

Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial.

Lana Keisha Apr 19, 2026 0

Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…

Read More
Advanced Materials Science

Breakthrough in MXene Synthesis Achieves Unprecedented Electrical Conductivity and Surface Precision Through Novel Molten Salt Technique

Nila Kartika Wati Apr 19, 2026 0

A collaborative research effort led by the Institute of Ion Beam Physics and Materials Research at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR)…

Read More
Laboratory Automation & Robotics

Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial

Lana Keisha Apr 12, 2026 0

Eli Lilly’s investigational drug, retatrutide, a pioneering first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, has delivered extraordinary results…

Read More
Advanced Materials Science

Breakthrough in MXene Synthesis Achieves Unprecedented Electrical Conductivity and Surface Precision Through Novel Molten Salt Technique

Nila Kartika Wati Apr 12, 2026 0

A collaborative research effort led by the Institute of Ion Beam Physics and Materials Research at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR)…

Read More

Posts pagination

1 2
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug componentBeyond the Brain: Groundbreaking Study Reveals Glioblastoma Sabotages Skull Bones and Hijacks the Immune SystemThe Ultimate Heat Limit Shattered: Newly Discovered Fire Amoeba Defies Thermal Boundaries for Complex LifeYale Researchers Uncover Molecular Mechanism Preventing Fertilization Opening New Paths for Infertility and Contraceptive Science
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactEliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic ProportionsMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
Merck and Moderna’s cancer vaccine is customized for each patient’s tumorAn Unbiased Look at Google Gemini Omni: Features, Costs, and Market ComparisonESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial CancerLight-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
Lana Keisha Oct 27, 2026
Data Science & Bioinformatics
An Unbiased Look at Google Gemini Omni: Features, Costs, and Market Comparison
Evan Lee Salim Oct 27, 2026
Pharmaceutical R&D
ESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial Cancer
Teuku Ryan Oct 27, 2026
Advanced Materials Science
Light-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
Nila Kartika Wati Oct 27, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ